Cargando…

Activation of diverse signaling pathways by oncogenic PIK3CA mutations

The PIK3CA gene is frequently mutated in human cancers. Here we carry out a SILAC-based quantitative phosphoproteomic analysis using isogenic knockin cell lines containing ‘driver’ oncogenic mutations of PIK3CA to dissect the signaling mechanisms responsible for oncogenic phenotypes induced by mutan...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xinyan, Renuse, Santosh, Sahasrabuddhe, Nandini A., Zahari, Muhammad Saddiq, Chaerkady, Raghothama, Kim, Min-Sik, Nirujogi, Raja S., Mohseni, Morassa, Kumar, Praveen, Raju, Rajesh, Zhong, Jun, Yang, Jian, Neiswinger, Johnathan, Jeong, Jun-Seop, Newman, Robert, Powers, Maureen A., Somani, Babu Lal, Gabrielson, Edward, Sukumar, Saraswati, Stearns, Vered, Qian, Jiang, Zhu, Heng, Vogelstein, Bert, Park, Ben Ho, Pandey, Akhilesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210192/
https://www.ncbi.nlm.nih.gov/pubmed/25247763
http://dx.doi.org/10.1038/ncomms5961
Descripción
Sumario:The PIK3CA gene is frequently mutated in human cancers. Here we carry out a SILAC-based quantitative phosphoproteomic analysis using isogenic knockin cell lines containing ‘driver’ oncogenic mutations of PIK3CA to dissect the signaling mechanisms responsible for oncogenic phenotypes induced by mutant PIK3CA. From 8,075 unique phosphopeptides identified, we observe that aberrant activation of PI3K pathway leads to increased phosphorylation of a surprisingly wide variety of kinases and downstream signaling networks. Here, by integrating phosphoproteomic data with human protein microarray-based AKT1 kinase assays, we discover and validate six novel AKT1 substrates, including cortactin. Through mutagenesis studies, we demonstrate that phosphorylation of cortactin by AKT1 is important for mutant PI3K enhanced cell migration and invasion. Our study describes a quantitative and global approach for identifying mutation-specific signaling events and for discovering novel signaling molecules as readouts of pathway activation or potential therapeutic targets.